NCT04906694 is a Phase 2 clinical trial of COVI-DROPS in Covid19, sponsored by Sorrento Therapeutics, Inc..

Who is sponsoring NCT04906694?

NCT04906694 is sponsored by Sorrento Therapeutics, Inc..

What drugs are being tested in NCT04906694?

Interventions in NCT04906694: COVI-DROPS, Placebo.

Is NCT04906694 still recruiting?

NCT04906694 is currently completed. Last updated 3 February 2022.

Last reviewed 2022-02-03 · How we verify

NCT04906694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)

Completed Phase 2 Last updated 3 February 2022

What this trial tests

Phase 2 trial testing COVI-DROPS in Covid19 in 97 participants. Completed in 13 January 2022.

Timeline

16 November 2021

Primary endpoint
13 January 2022

13 January 2022

Quick facts

Lead sponsor	Sorrento Therapeutics, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	97
Start date	16 November 2021
Primary completion	13 January 2022
Estimated completion	13 January 2022
Sites	18 locations across United States

Drugs / interventions tested

COVI-DROPS — full drug profile →
Placebo

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Sorrento Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have mild symptoms.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.
Pitiot A, Heuzé-Vourc'h N, Sécher T. · · 2022 · cited 45× · PMID 36134952 · DOI 10.3390/antib11030056
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.
Strohl WR, Ku Z, An Z, Carroll SF, et al · · 2022 · cited 31× · PMID 35476216 · DOI 10.1007/s40259-022-00529-7
Localized delivery of nanomedicine and antibodies for combating COVID-19.
Tu B, Gao Y, An X, Wang H, et al · · 2023 · cited 9× · PMID 36168329 · DOI 10.1016/j.apsb.2022.09.011

Verify or expand the search:

Other trials of COVI-DROPS

Trials testing the same drug.

NCT04900428 — Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK) · Phase 2 · terminated

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Sorrento Therapeutics, Inc. trials

Trials by the same sponsor.

NCT04118868 — Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. · Phase 1 · unknown
NCT05364840 — Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers · Phase 1 · completed
NCT04903327 — Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress · Phase 2 · terminated
NCT04037241 — Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases · Phase 2, PHASE3 · withdrawn
NCT04900428 — Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK) · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04906694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sorrento Therapeutics, Inc.
Last refreshed: 3 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04906694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing